Letter to the editor on the article by Kripp et al. ' 'Quality of life of older adult patients receiving docetaxel-based chemotherapy triplets for esophagogastric adenocarcinoma: a randomized study of the Arbeitsgemeinschaft Internistische Onkologie (AIO),'' Gastric Cancer (2014) 17:181-187.
There is a lack of quality-of-life (QoL) data from cancer trials [1, 2] . Therefore, the article by Kripp et al. [3] is to be welcomed. However, we have some queries and would like to see the following issues addressed by the authors: with regard to study design and report the result for the statistically significant difference at week 8 (and also refer to this result in the discussion). However, they mention neither that the data shown refer to the endpoint defined as the main QoL endpoint in [4] nor the conflicting conclusion. Clinical studies should be reported in accordance with the study protocol. We call for the regular publication of full protocols to help identify inaccurate and selective reporting.
